Bristol-Myers Squibb Company (BMY) Stock

Healthcare · Drug Manufacturers - General · Member of S&P 500

Bristol-Myers Squibb Company (BMY) closed at USD 59.28 on 2026-10-14, a change of +44.6 % over the past year, with a market capitalization of USD 123.73B.

Bristol-Myers Squibb Company recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Bristol-Myers Squibb Company key figures

Previous close

USD 59.28 (2026-10-14)

1-year change

+44.6 %

Market cap

USD 123.73B

Enterprise value

USD 157.71B

P/E ratio (trailing)

12.49

P/E ratio (forward)

9.14

EPS (trailing)

4.85

EPS (forward)

6.62

PEG ratio

16.51

Price to book

5.54

Revenue growth

5.7 %

Earnings growth

153.1 %

Dividend per share (trailing)

2.51

Short ratio

3.99

Employees

32,500

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Bristol-Myers Squibb Company and compare it with other stocks.